These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26990271)

  • 21. Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.
    Kirchberger MC; Hauschild A; Schuler G; Heinzerling L
    Eur J Cancer; 2016 Sep; 65():182-4. PubMed ID: 27501507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis.
    Tandon P; Bourassa-Blanchette S; Bishay K; Parlow S; Laurie SA; McCurdy JD
    J Immunother; 2018 Apr; 41(3):101-108. PubMed ID: 29401166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is increased colon subepithelial collagen layer thickness in diabetic patients related to collagenous colitis? An immunohistochemical study.
    Unal A; Guven K; Yurci A; Torun E; Gursoy S; Baskol M; Ozturk F; Arsav V
    Pathol Res Pract; 2008; 204(8):537-44. PubMed ID: 18423894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma.
    Hwang SJE; Park JJW; Wakade D; Chou S; Byth K; Fernandez-Penas P
    Melanoma Res; 2019 Apr; 29(2):172-177. PubMed ID: 30273233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
    Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
    N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
    Longoria TC; Tewari KS
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Two cases of granuloma annulare under anti-PD1 therapy].
    Charollais R; Aubin F; Roche-Kubler B; Puzenat E
    Ann Dermatol Venereol; 2018 Feb; 145(2):116-119. PubMed ID: 29221649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and Pathological Relevance of Drug-induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF/MEK Inhibitors.
    Ramondetta A; Ribero S; Conti L; Fava P; Marra E; Broganelli P; Caliendo V; Picciotto F; Guida M; Fierro MT; Quaglino P
    Acta Derm Venereol; 2020 Jan; 100(1):adv00001. PubMed ID: 31532537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of toxicities of immune checkpoint inhibitors.
    Spain L; Diem S; Larkin J
    Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
    Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.
    Pasquali S; Chiarion-Sileni V; Rossi CR; Mocellin S
    Cancer Treat Rev; 2017 Mar; 54():34-42. PubMed ID: 28189914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
    Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
    Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
    Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
    Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis.
    Puri A; Homsi J
    Melanoma Res; 2017 Oct; 27(5):519-523. PubMed ID: 28817445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management.
    Hwang SJ; Anforth R; Carlos G; Fernandez-Peñas P
    Actas Dermosifiliogr; 2017; 108(1):6-16. PubMed ID: 27642030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
    Simeone E; Ascierto PA
    J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy in melanoma: Recent advances and future directions.
    Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
    Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies.
    Choong ES; Lo S; Drummond M; Fogarty GB; Menzies AM; Guminski A; Shivalingam B; Clarke K; Long GV; Hong AM
    Eur J Cancer; 2017 Apr; 75():169-178. PubMed ID: 28236768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma.
    Metcalfe W; Anderson J; Trinh VA; Hwu WJ
    Discov Med; 2015 May; 19(106):393-401. PubMed ID: 26105702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.